Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why

Published on December 31, 2021

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.

Continue reading on website
Other news

Surprise Coronavirus Stimulus Checks: COLA To Boost Social Security Payments

December 31, 2021
The rumored fourth stimulus check is nowhere to be seen, but with the COVID-19 pandemic still not over, a surprise payment boost starting next month could offer some relief to...

5 Reasons to Add Avis Budget Group (CAR) Stock in Your Portfolio

December 31, 2021
Avis Budget (CAR) remains focused on structurally improving its business amid the pandemic through cost discipline and operational efficiencies.